BioPharma Resources

Drug Trial Radar · NCT03262012

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort® Turbuhaler® as an Active Control

Last checked: Nov 19, 2026Latest source record: May 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

416

Actual

Start

Aug 9, 2016

Primary completion

Jun 15, 2018

Study completion Jun 15, 2018

Sponsor

Lead sponsor
Pearl Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-Blind, Parallel Group, 28-Week Chronic Dosing, Multi-Center Long-term Extension Study to Assess the Safety and Efficacy in Japanese Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) compared with Symbicort® Turbohaler®

Conditions

  • COPD

Interventions

  • BGF MDI (PT010)Drug

    Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010

  • GFF MDI (PT003)Drug

    Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003

  • BFF MDI (PT009)Drug

    Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009

  • Symbicort® Turbohaler® Inhalation PowderDrug

    Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Post-baseline Newly Occurring or Worsening PCS (Potentially Clinically Significant) Clinical Chemistry ValuesTime frame: 28 Weeks
  2. Incidence of Post-baseline Newly Occurring or Worsening PCS Vital SignsTime frame: 28 Weeks
  3. Incidence of Post-baseline Newly Occurring or Worsening PCS ECG ValuesTime frame: 28 Weeks

Locations

79 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Bunkyō City, Japan

  • Research Site

    Chūōku, Japan

  • Research Site

    Chūōku, Japan

  • Research Site

    Chūōku, Japan

  • Research Site

    Date-gun, Japan

  • Research Site

    Fukuoka, Japan

  • Research Site

    Ginowan-shi, Japan

  • Research Site

    Hakata-shi, Japan

  • Research Site

    Hamamatsu, Japan

  • Research Site

    Hamamatsu, Japan

  • Research Site

    Hamamatsu, Japan

  • Research Site

    Higashiokitama-gun, Japan

  • Research Site

    Higashiosaka-shi, Japan

  • Research Site

    Himeji-shi, Japan

  • Research Site

    Hirakata-shi, Japan

  • Research Site

    Iizuka-shi, Japan

  • Research Site

    Iwata-shi, Japan

  • Research Site

    Izumo-shi, Japan

  • Research Site

    Izumo-shi, Japan

  • Research Site

    Kagoshima, Japan

  • Research Site

    Kahoku-gun, Japan

  • Research Site

    Kakogawa-shi, Japan

  • Research Site

    Kasaoka-shi, Japan

  • Research Site

    Kasuga-shi, Japan

  • Research Site

    Kishiwada-shi, Japan

  • Research Site

    Kiyose-shi, Japan

  • Research Site

    Kobe, Japan

  • Research Site

    Koga-shi, Japan

  • Research Site

    Kurashiki-shi, Japan

  • Research Site

    Kure-shi, Japan

  • Research Site

    Kure-shi, Japan

  • Research Site

    Kyoto, Japan

  • Research Site

    Kyoto, Japan

  • Research Site

    Kyoto, Japan

  • Research Site

    Kyoto, Japan

  • Research Site

    Kyoto, Japan

  • Research Site

    Maebashi, Japan

  • Research Site

    Matsumoto-shi, Japan

  • Research Site

    Matsusaka-shi, Japan

  • Research Site

    Meguro-ku, Japan

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.